oxiracetam
Small moleculeexperimental
Oxiracetam is a nootropic drug of the racetam family and a very mild stimulant. Several studies suggest that the substance is safe even when high doses are consumed for a long period of time. However, the mechanism of action of the racetam drug family is still a matter of research. Oxiracetam is not approved by Food and Drug Administration for any medical use in the United States. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 26, 2017 (NCT04205565)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- AcetylcholinesteraseINHIBITOR
ACHE inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)CN1CC(O)CC1=O- Mol. weight
- 158.16 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOxiracetam ↗
- ChEMBLCHEMBL36633 ↗
Also known as
- hydroxypiracetam
- neuromet
- oxiracetam
- oxiracetam
- oxiracetam
- oxiracetam
- oxiracetam
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04205565 | Phase 2 | Jul 26, 2017 | Nanjing Yoko Biomedical Co., Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nanjing Yoko Biomedical Co., Ltd. | For profit | 1 | 1 | 1 | 2017 |
1 organizations
Page 1 / 1